Herbesser

Quick links to important sections

Herbesser

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Herbesser

Property Description
Active Ingredient Diltiazem hydrochloride
Form Tablet, extended-release capsule, injection solution
Pharmacological Class Calcium-channel blocker (non-dihydropyridine)
General Purpose Managing Angina, Hypertension, and Tachyarrhythmias
Origin Synthetic compound (Benzothiazepine derivative)

Defining Herbesser: Classification and Origin

Herbesser is a common trade name for the active drug substance Diltiazem hydrochloride, which is classified as a prescription-only medication (POM) used to manage cardiovascular conditions. Chemically, Diltiazem is a synthetic compound derived from the Benzothiazepine chemical structure. The availability of both immediate-release tablets and extended-release capsule forms under the Herbesser name reflects the clinical need for varied release profiles in treating chronic heart conditions.

Diltiazem is manufactured as a single-ingredient product, available in several pharmaceutical preparations for both oral and intravenous (IV) administration. The synthetic nature of this Benzothiazepine derivative is supported by pharmacological studies, which ensure its specific and reliable action on the cardiovascular system.

What Pharmacological Class Does Diltiazem Belong To?

Diltiazem is formally categorized within the pharmacological class of calcium-channel blockers, also widely known as a calcium antagonist or Ca^2+ antagonist, because it regulates the flow of calcium ions into cardiac and vascular cells. This mechanism is crucial for its function as both an antihypertensive drug and a Class IV antiarrhythmic agent.

A distinguishing feature is Diltiazem's designation as a non-dihydropyridine entity. This balanced action profile allows it to influence both the vascular system and the heart's electrical conduction system, making it essential for managing complex cardiovascular scenarios that require simultaneous control over systemic pressure and heart rate.

General Therapeutic Purpose of This Cardiovascular Drug

The core general therapeutic purpose of Diltiazem is to regulate the body's cardiovascular performance by reducing the physical strain placed on the heart. By acting on L-type calcium channels, the drug promotes coronary vasodilation, which helps alleviate chest pain, such as that associated with Angina pectoris, by improving blood supply to the heart muscle.

This regulating action is broadly indicated for achieving long-term control of high blood pressure, known as Systemic arterial hypertension. Furthermore, Diltiazem’s influence on the heart’s electrical pathways helps stabilize rapid, irregular beats, specifically supraventricular tachyarrhythmias, a therapeutic use that is clinically recognized in major treatment guidelines.

What side effects are possible with Herbesser?

Possible Side Effects and Safety Information

The safety profile of Herbesser (diltiazem hydrochloride) includes a range of potential side effects, from common, expected reactions related to its function as a calcium channel blocker to rare, serious adverse events that require immediate medical attention.

Commonly Reported Adverse Reactions

Side effects that are frequently reported or have been observed in clinical studies often involve the cardiovascular, gastrointestinal, and nervous systems. These include:

  • Cardiac/Vascular: Bradycardia (slow heart rate), first-degree atrioventricular (AV) block, flushing, and edema (swelling, particularly in the lower limbs).
  • Gastrointestinal: Constipation, nausea, and dyspepsia.
  • Nervous System: Headache, dizziness, and fatigue/asthenia.

Serious Adverse Reactions

Though rare, regulatory documents identify severe, clinically significant adverse reactions that have been reported with diltiazem therapy. Signs of these conditions warrant prompt medical evaluation:

  • Severe Cardiac Events: Second- or third-degree AV block, sick sinus syndrome, severe bradycardia, and new onset or worsening of congestive heart failure.
  • Hepatic Injury: Acute liver injury, characterized by significant elevations in liver enzymes and signs such as jaundice (yellowing of the skin or eyes) or unusual fatigue.
  • Severe Skin Reactions (SCARs): Serious hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis, which can present as fever and widespread rash, blistering, or peeling skin.

Safety Precautions and Restrictions

The drug is typically contraindicated in patients with certain severe pre-existing heart conditions, such as severe hypotension, second- or third-degree AV block (unless a functioning pacemaker is present), or sick sinus syndrome. Caution is generally advised for use in patients with impaired ventricular function or existing liver or kidney dysfunction. Due to the potential for dizziness and hypotension, patients are advised to use caution when performing activities that require alertness.

Overdose and Emergency Response

Herbesser Overdose and When to Seek Help

Overdose of Herbesser (Diltiazem hydrochloride) is associated with severe, potentially life-threatening cardiovascular effects that necessitate seeking immediate medical attention.

Officially documented overdose presentations include severe hypotension, severe bradycardia, and pronounced cardiac conduction disturbances such as second- or third-degree atrioventricular block and sinus arrest. Regulatory documents note that overdose has been associated with fatal outcomes, cardiogenic shock, and cardiac failure. Exposure to extended-release formulations poses a risk of delayed onset and prolonged toxicity.

Immediate medical help must be sought for any suspected overdose. Management specified in regulatory labeling is symptomatic and supportive treatment, including gastric lavage and activated charcoal for recent oral ingestion. Specific procedural interventions described involve the use of intravenous calcium, vasopressors, and atropine, or cardiac pacing to manage severe cardiodepression. Due to the high risk, continuous cardiac monitoring and prolonged observation are required, especially for the extended-release product, which may necessitate monitoring for at least 48 hours.

Therapeutic Uses of Herbesser

What Herbesser Treats: Main Uses and Benefits

Herbesser (Diltiazem) is a medication whose use is relevant across several cardiovascular domains. It is commonly used for managing conditions that require relief for symptoms related to hypertension, chronic stable angina, and certain supraventricular tachyarrhythmias.

In clinical settings, this medicine is relevant when supportive symptom management is appropriate for conditions characterized by recurrent chest pain (including pain due to coronary artery spasm) and for abnormally rapid heartbeats. It is also applied in conditions marked by increased physiological stress associated with persistently elevated arterial pressure. This approach provides support that contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods. It is commonly used to help with symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Episodic Discomfort

Herbesser may be part of symptomatic management for conditions involving episodic manifestations, such as Raynaud's phenomenon, and is relevant for easing the intensity and frequency of associated discomfort in the extremities.

Regulatory References

  1. NIH MedlinePlus overview on Diltiazem

Eligibility and Restrictions for Use

Who can and cannot use Herbesser?

Eligibility for Herbesser (Diltiazem) is defined by official regulatory documents based primarily on cardiac function and patient demographics.

Eligibility Status Applicable Population/Condition
Absolutely Contraindicated Sick sinus syndrome or second-/third-degree AV block (except with a functioning pacemaker); Severe hypotension (systolic BP below 90 mmHg); Cardiogenic shock; Acute MI with pulmonary congestion; Atrial fibrillation/flutter with an accessory bypass tract (e.g., WPW syndrome); Documented hypersensitivity to the drug; Nursing mothers (in some regions).
Use with Caution Impaired renal function; Impaired hepatic function; Congestive heart failure or impaired ventricular function.

Age-Related Eligibility:

Use in the pediatric population is not recommended because safety and efficacy have not been established in children. Older adults (geriatric population) may require a cautious approach and potential dose adjustment due to the increased prevalence of age-related organ impairment. During pregnancy, use is only recommended if the potential benefit justifies the potential risk to the fetus, as Diltiazem is teratogenic in animal studies. The most critical restrictions are the absolute exclusions for unstable cardiac conduction and hemodynamic compromise, as specified in regulatory labeling.

What should I know about interactions with other medicines?

Herbesser (Diltiazem) interactions are defined in official regulatory documents by its ability to affect drug metabolism and cardiac function. Diltiazem is a moderate inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme system. This inhibition can increase the systemic exposure of other medicines primarily metabolized by CYP3A4, such as Midazolam, Triazolam, Cyclosporine, and certain statins.

Interaction Type Examples of Affected Medicines Outcome as Documented
Metabolic (CYP3A4) Cyclosporine, Midazolam, Triazolam Increased plasma concentration (AUC/Cmax) of co-administered drug
Pharmacodynamic Beta-blockers, Digoxin, Anesthetics Risk of additive effects on cardiac conduction/rate

Regulatory agencies have established combinations that are formally contraindicated. These include co-administration with Dantrolene (infusion) and Ivabradine due to the risk of severe adverse cardiac events. Additionally, co-administration with Cimetidine significantly increases Diltiazem plasma levels. The official labeling also notes that alcohol should be avoided with certain extended-release forms due to the risk of increased drug release and systemic exposure. Dosage adjustments may be required for other CYP3A4 substrates, particularly in patients with impaired renal or hepatic function.

Mechanism of Action

Core Action on L-Type Calcium Channels

Herbesser (Diltiazem) functions as an antagonist and blocker of Voltage-dependent L-type calcium channels (CaV 1.2) found in the heart and arteries. This interaction prevents the essential influx of calcium ions, which are critical for both muscle contraction and electrical impulse generation. The resulting cellular effect limits the key molecular step that initiates activity in these cells.


Dual Modulation of Cardiac Rhythm and Arterial Tone

The mechanism involves simultaneous engagement of the cardiac electrical conduction system and the vascular smooth muscle tone. By limiting calcium influx, the drug directly affects the heart’s electrical control centers (SA and AV nodes), establishing negative chronotropy (slower rhythm) and negative dromotropy (slower electrical signal transmission). Concurrently, the inhibition of calcium in the arterial walls causes vasodilation, resulting in decreased systemic vascular resistance (afterload).


Physiological Consequence: Reduced Myocardial Workload

The combined mechanistic effect of reducing heart rate, slowing electrical activity, and promoting vasodilation ultimately leads to a decrease in the physical workload placed on the heart muscle. This synchronized cardiac and vascular modulation establishes a state of reduced electrical and contractile activity, and influences the systemic resistance profile on the cardiovascular system.

Dosage and Administration Information

Herbesser (Diltiazem) is administered through two routes: oral for long-term chronic management and intravenous (IV) for acute, short-term situations. The choice of administration route and dosing regimen is governed by the specific pharmaceutical formulation used.

Oral treatment utilizes various strengths, with extended-release forms typically taken once daily. Initial doses range from 120 mg to 240 mg, with maintenance doses potentially reaching a maximum of 540 mg/day. Immediate-release tablets are generally administered in divided doses four times per day, often before meals and at bedtime. To maintain the drug's intended action profile, extended-release capsules and tablets must be swallowed whole and must not be crushed or chewed. Dosage adjustments are made gradually, with at least 7 to 14 days separating each change to allow the full response to be observed.

For acute conditions, the IV solution is administered as an initial bolus followed by a continuous infusion that is used for durations of no longer than 24 hours. Intravenous administration must occur in a setting with continuous ECG and blood pressure monitoring. For specific patient populations, initial oral dosing should commence at the lower end of the range for older adults and patients with known hepatic or renal impairment. The medication is not recommended for the pediatric population due to a lack of established safety and efficacy data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Herbesser


Evidence for Use in Chronic Stable Angina

Research for chronic stable angina (chest discomfort related to physical exertion) was studied through short-term, placebo-controlled, randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity and evaluated outcomes related to physical discomfort and daily functioning. Studies explored functional outcomes, such as exercise duration, and symptom endpoints, like the reported frequency of chest pain episodes. Findings describe patterns observed where researchers measured a change in the frequency of self-reported anginal attacks compared to the start of the trial. However, data for long-term cardiovascular outcomes, such as the effects on heart attack rates or overall survival over many years, are not fully established by these specific trials.


Evidence for Use in Research on Blood Pressure (Hypertension)

Research explored Systemic Arterial Hypertension (high blood pressure) primarily through multicenter randomized controlled trials. These studies monitored biomarkers, specifically the change in both systolic and diastolic blood pressure measurements when a person was at rest or during exercise. In these trials, findings describe patterns observed where researchers measured changes in blood pressure compared to baseline. Long-term comparative trials described patterns of cardiovascular event rates similar to those observed in trials of other drug classes. While the evidence level is high for studies on blood pressure changes, the long-term effects are not fully established across all possible comparative scenarios.


Evidence in Special Populations and Specific Conditions

Studies observed Diltiazem in older adults, and these studies report how symptoms evolved in the observed populations. However, for the pediatric population (children and adolescents), evidence remains limited. Regulatory summaries indicate that the safety and effectiveness have not been established in this group based on the available research.

For the condition of Coronary Vasomotor Dysfunction (CVDys), research has explored short-term symptom changes in specific trials. Findings were mixed: while some research highlights changes measured on specific coronary markers, recent dedicated trials reported that there was no substantial difference in overall patient-reported symptom relief compared to placebo. The certainty remains low regarding research outcomes for patient-reported symptoms in this specific population.

Key Studies & References NIH MedlinePlus: Diltiazem (General Therapeutic Uses and Benefits)

Frequently Asked Questions (FAQ)

Common questions about Herbesser (FAQ)


Q: How quickly should I expect Herbesser to start affecting my heart rate?

The immediate-release formulation of diltiazem is estimated to begin its therapeutic effects within 30 to 60 minutes after being taken. For the extended-release formulation, the full effect on blood pressure typically becomes evident after approximately 14 days of regular, chronic therapy.


Q: How long does the effect of a single dose of Herbesser usually last?

The duration of effect is determined by the specific formulation used. The immediate-release form has a plasma elimination half-life of approximately 3.0 to 4.5 hours. Extended-release forms are designed to provide a more prolonged release of the medication, resulting in a longer apparent elimination half-life, generally ranging from 5 to 9.5 hours.


Q: What makes Herbesser different from other common heart medications?

Herbesser (diltiazem) is officially classified as a non-dihydropyridine calcium channel blocker. This means that, based on its regulatory profile, it simultaneously acts on both the blood vessel walls, promoting relaxation, and on the heart's electrical conduction system, which helps to slow the heart rate and electrical signals.


Q: Does Herbesser interact with common supplements like magnesium or fish oil?

The official product labeling does not specifically list common supplements such as magnesium or fish oil as interacting agents. However, patients are generally advised in the regulatory information to inform their healthcare providers about all prescription, over-the-counter medicines, vitamins, herbal products, and other supplements they are using.


Q: Is it normal for my blood pressure to fluctuate slightly after starting Herbesser?

Diltiazem works by decreasing blood pressure. Regulatory warnings indicate that it may occasionally result in symptomatic hypotension, which is a drop in blood pressure that causes symptoms like dizziness. If any significant or concerning fluctuations are observed, the product label advises consulting a healthcare professional.


Q: Can I take cold and flu medicine while I am on Herbesser?

Cold and flu medicines can contain ingredients that may affect blood pressure or heart rate. Official product information advises caution with medicines that affect cardiac conduction, as diltiazem may contribute to additive effects. The regulatory documents advise consulting a healthcare provider before combining diltiazem with any over-the-counter medications.


Q: Do the side effects of Herbesser generally lessen over time?

Regulatory documents note that some adverse reactions, particularly certain skin-related events, have been described as transient and may resolve even with the continued use of diltiazem. However, the official label does not contain a general statement about the lessening of all common side effects over time.


Q: How is Herbesser eliminated from the body?

Herbesser is extensively metabolized, or processed, mainly by the liver through the CYP450 enzyme system. It is then eliminated from the body by the kidneys and in bile. Only a small percentage of the original, unchanged drug is typically found in the urine.


Q: Does Herbesser come in different strengths or formulations (e.g., immediate release vs. sustained release)?

Yes, diltiazem is available in multiple oral forms. This includes immediate-release tablets and various extended-release capsules and tablets, all offered in different strengths.


Q: Is it common to feel dizzy or lightheaded when first starting Herbesser?

Dizziness and hypotension (low blood pressure) are known adverse events associated with this medication. Official warnings indicate that the risk of dizziness or symptomatic low blood pressure may be increased when treatment is first started or just after a dosage increase.


Q: Can Herbesser cause a persistent dry cough like some other heart medicines?

In clinical trials for extended-release diltiazem, 'increased cough' was reported as an adverse event at a low frequency. However, the official regulatory label does not specifically describe this event as a 'persistent dry cough.'


Q: What types of foods or drinks should I limit while taking Herbesser?

Official patient information advises patients to limit alcohol intake while on the medication. Patients are also advised to avoid excessive consumption of grapefruit and grapefruit juice, as these substances can increase the concentration of diltiazem in the bloodstream.


Q: Is Herbesser safe for use in older adults?

Official product information advises a cautious approach for use in the geriatric population. Patients aged 60 years and older may be sensitive to lower doses, and initial oral dosing is generally recommended to commence at the lower end of the official range.


Q: Is it necessary to have regular blood tests while on Herbesser?

The regulatory documents state that laboratory parameters of both kidney (renal) and liver (hepatic) function should be monitored at regular intervals. This is considered a necessary precaution due to how the drug is metabolized and eliminated by the body over prolonged periods.


Q: Can Herbesser make me feel more tired than usual?

Yes, official labeling lists fatigue and asthenia (a medical term for generalized weakness or lack of energy) as commonly reported adverse reactions observed in clinical studies.


Q: How does the sustained-release version of Herbesser work compared to the standard version?

The extended-release forms are specifically designed to release the active drug substance gradually over a long period. This mechanism allows the medication to be taken once-daily or twice-daily, helping to maintain stable therapeutic blood levels. The standard immediate-release tablets generally require more frequent dosing.


Q: Do many people need to adjust their dosage of Herbesser after starting it?

Official prescribing information indicates that dosage adjustments, or titration, are a standard part of the treatment process. Doses are typically adjusted based on the patient’s clinical response, with changes generally recommended to be made gradually over intervals of 7 to 14 days.


Q: Is it common for doctors to prescribe Herbesser along with a diuretic (water pill)?

Diltiazem has an additive blood pressure-lowering effect when used with other agents intended for high blood pressure. Combination therapy, such as using diltiazem with a diuretic, is a common clinical approach, but often requires careful dosage adjustment of the medications involved.


Q: What is the risk of having a drug interaction with Herbesser?

Herbesser is known to be a moderate inhibitor of the CYP3A4 enzyme, a major enzyme responsible for metabolizing many other medications. This inhibition creates a potential risk for the concentration of co-administered drugs in the body to increase, necessitating caution and potential dose adjustments.


Q: Can Herbesser cause problems with sleep or insomnia?

Yes, insomnia, which is difficulty sleeping, is listed in the official documentation as an infrequently reported adverse event associated with the use of this drug.


Q: Is Herbesser ever used for conditions not related to the heart?

The drug is officially approved and indicated only for cardiovascular conditions, including hypertension, angina, and supraventricular tachyarrhythmias. The regulatory label does not contain information regarding its use for conditions not related to the heart.


Q: Are there any known severe allergic reactions to Herbesser?

Yes, the official label identifies severe skin reactions (SCARs), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis, as rare but clinically serious adverse reactions that have been reported.


Q: What should I tell my dentist or surgeon about before a procedure if I take Herbesser?

The product label indicates caution regarding the co-administration of diltiazem with general anesthetics due to a risk of potential additive effects on heart rate and electrical conduction. Due to this potential interaction, regulatory guidance recommends that patients disclose all medications they are taking to their healthcare providers before a procedure.


Q: Does Herbesser affect fertility or sexual health?

Animal studies showed no evidence of impaired fertility in male and female rats. Regarding sexual health, official adverse event reporting lists impotence in the urogenital system as an infrequently reported event in humans.

How should Herbesser be stored and disposed of?

The official regulatory requirements for storing and disposing of Herbesser (Diltiazem Hydrochloride) are focused on maintaining drug stability and preventing accidental exposure.

Storage & Disposal Scope

Labeled storage temperature requirements: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F).
Light/moisture protection requirements: The medicine must be protected from excess heat, moisture, and light. Keep the container tightly closed.
Child-protection storage requirements (if stated): Keep out of sight and reach of children (Warning: Keep out of reach of children).
Disposal instructions (as documented in government sources): Disposal should be managed through a community drug take-back program if available. Otherwise, mix the product with an undesirable substance (e.g., used coffee grounds), place it in a sealed container, and discard it in the household trash. Do not flush the medicine unless specifically instructed by the regulatory label.

Storage/Disposal Classifications

Storage condition type: Controlled Room Temperature
Storage-context constraints (as defined in official documents): Protect from Excess Heat and Moisture. Keep container Tightly Closed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Herbesser found in:

A-Z Index: